Discontinuing Prophylactic Transfusions Used to Prevent Stroke in Sickle Cell Disease
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Prophylactic transfusion prevents strokes in children with sickle cell anemia who have abnormalities on transcranial Doppler ultrasonographic examination. However, it is not known how long transfusion should be continued in these children. METHODS: We studied children with sickle cell disease who had a high risk of stroke on the basis of a transcranial Doppler screening examination and who had received transfusions for 30 months or longer, during which time the Doppler readings became normal. The children were randomly assigned to continued transfusion or no continued transfusion. Children with severe stenotic lesions on cerebral magnetic resonance angiography were excluded. The composite primary end point was stroke or reversion to a result on Doppler examination indicative of a high risk of stroke. RESULTS: The study was stopped after 79 children of a planned enrollment of 100 underwent randomization. Among the 41 children in the transfusion-halted group, high-risk Doppler results developed in 14 and stroke in 2 others within a mean (+/-SD) of 4.5+/-2.6 months (range, 2.1 to 10.1) of the last transfusion. Neither of these events of the composite end point occurred in the 38 children who continued to receive transfusions. The average of the last two transcranial Doppler results before transfusion was started was the only predictor of the composite end point (P=0.05). CONCLUSIONS: Discontinuation of transfusion for the prevention of stroke in children with sickle cell disease results in a high rate of reversion to abnormal blood-flow velocities on Doppler studies and stroke. (ClinicalTrials.gov number, NCT00006182.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the approximately 22% of children who did not achieve normalization of transcranial Doppler velocity in spite of optimal transfusion in the trial were also protected from stroke (162).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [162]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Adams, R. J., McKie, V. C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., Abboud, M., Gallagher, D., Kutlar, A., Nichols, F. T., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807023390102 · Cited by 1,866
Cerebrovascular accidents in sickle cell disease: rates and risk factors.
(1998) · PubMed · doi:10.1182/blood.v91.1.288 · Cited by 1,694
Rother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Dams, R. O. J. A., Ie, V. I. C. M. C. K., Su, L. E. H., Iles, B. E. F., Ichinsky, E. L. V., Egelow, C. H. P., Bboud, M. I. A., Allagher, D. I. G., Utlar, K., Ichols, F. E. T. N., et al. (2015) · Cited by 1,338
Steinberg, M. H., Barton, F., Castro, O., Pegelow, C. H., Ballas, S. K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1645 · Cited by 931
Goldstein, L. B., Adams, R., Becker, K., Furberg, C. D., Gorelick, P. B., Hademenos, G., Hill, M., Howard, G., Howard, V. J., Jacobs, B., et al. (2001) · Stroke · doi:10.1161/01.str.32.1.280 · Cited by 905
The Use of Transcranial Ultrasonography to Predict Stroke in Sickle Cell Disease
Adams, R., McKie, V., Nichols, F., Carl, E., Zhang, D.-L., McKie, K., Figueroa, R., Litaker, M., Thompson, W., & Hess, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202273260905 · Cited by 658
Research works printed but not linked: 2
- Ohene-Frempong K, 1998, Blood, 91, 288
- Walters MC, 2000, Blood, 95, 1918
Cited by
Heart Disease and Stroke Statistics—2011 Update: A Report From the American Heart Association
Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Adams, R. J., Berry, J. D., Brown, T. M., Carnethon, M. R., Dai, S., de Simone, G., Ford, E. S., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182009701 · Cited by 6,149
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Meschia, J. F., Bushnell, C., Boden-Albala, B., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Elkind, M. S. V., Fornage, M., et al. (2014) · Stroke · doi:10.1161/str.0000000000000046 · Cited by 2,650
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members
Yawn, B. P., Buchanan, G. R., Afenyi-Annan, A. N., Ballas, S. K., Hassell, K. L., James, A. H., Jordan, L., Lanzkron, S. M., Lottenberg, R., Savage, W. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.10517 · Cited by 1,599
Metadata
- Authors
- The Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators
- Affiliations
- Augusta University (US)
- Corresponding author
- The Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-12-29
- Volume
- 353
- Issue
- 26
- Pages
- 2769-2778
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1498156640
- Cited by
- 635
- References
- 27
- Citations by year
- 2026: 23 · 2025: 12 · 2024: 31 · 2023: 22 · 2022: 29 · 2021: 27 · 2020: 34 · 2019: 25 · 2018: 35 · 2017: 37 · 2016: 43 · 2015: 25 · 2014: 32 · 2013: 32 · 2012: 45
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (U01HL052193, U01HL052016)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Keywords
- sickle cell disease, stroke prevention, prophylactic transfusion, transcranial Doppler screening, cerebral blood flow velocity, children
- MeSH terms
- Adolescent, Adult, Anemia, Sickle Cell, Blood Flow Velocity, Blood Transfusion, Brain, Child, Female, Humans, Magnetic Resonance Imaging, Male, Risk, Chelation Therapy, Ultrasonography, Doppler, Transcranial, Stroke, Middle Cerebral Artery, Withholding Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discontinuing Prophylactic Transfusions Used to Prevent Stroke in Sickle Cell Disease. https://app.cochat.ai/papers/10.1056/nejmoa050460
- The paper
- The Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. (2005). Discontinuing Prophylactic Transfusions Used to Prevent Stroke in Sickle Cell Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmoa050460
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.